Wednesday broker round-up
8th Aug 2012 09:57
AstraZeneca: Jefferies raises target from 2,975p to 3,100p, hold rating kept. Avon Rubber: Investec reiterates hold rating and 315p target. BTG: Jefferies maintains hold rating and 410p target. Cobham: Jefferies reiterates buy recommendation and 230p target; Investec keeps sell rating and 200p ta
Read moreLondon open: Stocks slip on concerns over Greece
8th Aug 2012 09:02
- S and P cuts Greek outlook to 'negative' - Markets await BoE inflation report - StanChart rebounds after yesterday's sell-off UK stocks slipped in the opening hour on Wednesday, with the Footsie pulling back after a four-month high, after Greece's long-term sovereign rating outlook was cut by Sta
Read moreBTG takes a hit after Astra halts CytoFab development
8th Aug 2012 07:34
Specialist healthcare group BTG revealed on Tuesday that it will take a one-off charge after disappointing results from its 'CytoFab' study meant that further development of the drug has been halted. The group has received top-line data from an AstraZeneca study comparing the efficacy and safety of
Read moreBroker tips: IAG, AstraZeneca, Berkeley
6th Aug 2012 11:25
Credit Suisse has downgraded its recommendation for British Airways and Iberia owner International Consolidated Airlines Group, otherwise known as IAG, from 'outperform' to 'neutral' on the back of risks to 2013 consensus estimates. IAG reported a second-quarter loss of €4m last week and revealed g
Read moreBroker snap: Astra's a top pick in pharma sector, says UBS
6th Aug 2012 11:17
UBS has reviewed its coverage for the European pharmaceuticals sector, highlighting that, for that the first time in five to seven years, the 'generics cliff' is coming out of forecasts. Following second-quarter results from pharma majors which provide visibility on full US generics, UBS has reiter
Read moreMonday broker round-up
6th Aug 2012 08:26
AstraZeneca: UBS ups target from 3,500p to 3,600p, buy rating kept. Berkeley: Investec raises target from 1,500p to 1,560p, buy rating kept. Catlin: Nomura reiterates buy rating and 506p target. Centrica: Deutsche Bank downgrades to hold from buy, target cut from 365p to 320p. Falkland Oil and G
Read moreFriday broker round-up -UPDATE
27th Jul 2012 09:54
African Minerals: Goldman Sachs upgrades to buy. AG Barr: Investec reiterates buy recommendation and 485p target; Shore Capital downgrades to hold; N+1 Brewing downgrades to hold. AstraZeneca: Nordea downgrades to sell. Barclays: Investec maintains buy rating and 240p target. BG Group: UBS cuts
Read moreGeneric competition dents sales at Astra - UPDATE
26th Jul 2012 16:37
Gross margins at AstraZeneca held up well in the first quarter, but the pharmaceuticals giant saw sales tumble as generic competition to its drugs ramped up. Astra, which reports in dollars, saw total revenues in the three months to June 30th of $6.66bn, a 21% drop on 2011 and well below the consen
Read moreLondon midday: Stocks jump after Draghi comments
26th Jul 2012 11:43
- Draghi pledges to do whatever it takes - Greece still on investors' minds - Markets digest a ton of results After a pretty flat start on the back of a flurry of mixed corporate earnings in London, the Footsie rocketed in late morning after some comments from the European Central Bank (ECB) Presid
Read moreAstra's profits fall as generics swallow market share
26th Jul 2012 08:03
AstraZeneca, the UK's second biggest pharma company, is sticking to its full year guidance despite a continuing slump in profits as competition from generic drugs heats up. Astra, which reports in dollars, saw core profits before tax of $2.164bn between April and June, a decline on 2011 of 33%, or
Read moreBig caps round-up: Shell, Lloyds, BG Group ...
26th Jul 2012 07:30
An extraordinary number of FTSE 100 companies released updates on Thursday morning. This is a round-up of the key points for each. AstraZeneca: Revenue for the second quarter was $6,660m, down 18% at constant exchange rates (CER). Core earnings per share (EPS) was $1.53 in the second quarter, a 6%
Read moreThursday preview: Deluge of updates expected
25th Jul 2012 16:26
Suspicions that the City is trying to get all of its business out of the way before the onset of the London Olympics are supported by the barrage of company results due on Thursday. Among the heavyweights expected to report are Astra, BG, BSkyB, Centrica, Compass, Capital Shopping, Intertek, Invens
Read moreWeek ahead: Hammerson, ARM, AstraZeneca
20th Jul 2012 10:30
Next week looks like a busy week for corporate trading statements and results, as blue chips begin to update the market on their performance at the interim stage, including FTSE 100 peers Hammerson, ARM Holdings and AstraZeneca. Retail-focused real estate investment trust (REIT) Hammerson is expect
Read moreTuesday broker round-up
17th Jul 2012 08:15
ARM: Citigroup cuts target from 730p to 600p, buy recommendation maintained. AstraZeneca: Bernstein reduces target from 3,037p to 3,002p, market perform rating kept. Beazley: JP Morgan Cazenove raises target from 147p to 155p, neutral rating kept. Bodycote: JP Morgan Cazenove cuts target from 437
Read moreTuesday broker round-up - UPDATE
10th Jul 2012 08:18
WPP: JP Morgan upgrades to outperform from neutral. AMEC: BarCap raises target from 1,340p to 1,350p, underweight rating kept. ASOS: Peel Hunt keeps buy rating and 1,800p target. AstraZeneca: BarCap keeps equal weight rating. Betfair: Nomura cuts target from 1,070p to 946p, buy rating unchanged.
Read more